DWAW yields 0.78% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, DWAW + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DWAW + JNJ for your $10,000?
Alpha-Seeking Complement to Broad Based Exposure – Broad based indexes, by their nature, have the good and the bad, the strong and the weak. DWAW seeks to add alpha using Dorsey Wright’s historically successful trend following process and investment modeling that looks to identify the strongest asset classes from the weaker performers. Active Management Advantage – Many ETFs passively invest owning the majority of the stocks represented in their benchmark index, including those with less than attractive investing attributes. DWAW’s investment process systematically screens a broad variety of asset classes in the FSM All Cap World investment universe for inclusion or removal from its highly tactical, active portfolio. Asset Class Rotation – Owning or even avoiding certain asset classes – domestic or foreign, small or large cap, growth or value, factor or market based – is an important determinant of portfolio success. Asset classes rotate in and out of season. Sometimes those trends last for years, other times for months. By investing in the highest FSM ranked funds, DWAW seeks to capture the growth of those asset classes demonstrating the greatest relative strength while avoiding the weakest. Systematic Defense – Because we believe avoiding severe losses helps to preserve capital and can contribute to good performance over time, DWAW uses a rules-based approach to tactically add cash or short term fixed income exposure to the portfolio when momentum indicators are triggered. The temporary defensive position is to try to shield the portfolio from certain catastrophic market types.
Full DWAW Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.